We aimed to determine the genotype distribution, allele frequency, and prognostic impact of \textit{IDH1/2}, \textit{TET2}, and \textit{ASXL1} single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs). \textit{TET2} (rs763480), \textit{ASXL1} (rs2208131), and \textit{IDH1} (rs11554137) variant homozygous genotype frequencies were found at rates of 1.5%, 9.2%, and 2.3%, respectively. No \textit{IDH2} SNP was identified. \textit{IDH1} and \textit{TET2} frequencies were 5% in essential thrombocythemia (ET) and 1.7% in ET and 5% in primary myelofibrosis (PMF), respectively. \textit{ASXL1} frequencies were 8.3%-10% in MPN subgroups. The \textit{TET2} mutant allele T and \textit{ASXL1} mutant allele G had the highest frequencies with 0.272 in the PMF and 0.322 in the polycythemia vera (PV) group, respectively. There was no impact of the SNPs on prognosis. \textit{IDH1} frequency in MPNs was found similar to the literature. \textit{ASXL1} frequencies were similar between ET, PV, and PMF patients. The \textit{ASXL1} and \textit{TET2} allele frequencies of the Turkish population are similar to those of the European population. The role of SNPs in MPNs might be further evaluated in larger multicenter studies.

**Keywords:** \textit{TET2}, \textit{ASXL1}, \textit{IDH1}, \textit{IDH2}, Single nucleotide polymorphisms, Ph-negative myeloproliferative neoplasms

---

**Introduction**

Philadelphia-negative myeloproliferative neoplasms (MPNs) are clonal disorders classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPNs are dependent on hypersensitivity or anomalies in cytokine regulation [1,2]. Some genes have been reported to be involved in the pathogenesis of MPNs, such as \textit{IDH1} (isocitrate dehydrogenase), \textit{IDH2}, \textit{TET2} (ten–eleven translocation 2), and \textit{ASXL1} (additional sex combs-like 1).

\textit{IDH1/2} encodes enzymes that catalyze the oxidative decarboxylation of isocitrate to \(\alpha\)-ketoglutarate [3]. The frequency of \textit{IDH1/2} mutation was 4% in MPNs, 0.8% in ET, 1.9% in PV, and 4.1% in PMF [4,5]. These mutations in PMF were reported as independent predictors of leukemic transformation [6].

\textit{ASXL1} encodes a member of the chromatin–binding proteins and is involved in epigenetic regulation of gene expression [7]. \textit{ASXL1} mutations are rare in ET and PV (<7%) but are frequent...
in PMF (19-40%) [3,7]. Worsened survival was reported in PMF patients with mutated ASXL1 [8].

TET proteins are enzymes that can convert 5-methylcytosine to 5-hydroxymethylcytosine [9]. TET2 mutation frequency was 16% in PV, 5% in ET, and 17% in PMF. Previous research did not identify an impact of TET2 mutations on survival or leukemic transformation [10].

Although the prognostic impact of these mutations has been investigated in some studies, there is still limited information available [6,8,10]. In this study, we focused only on single nucleotide polymorphisms (SNPs) in the ASXL1, TET2, and IDH1/2 genes. We aimed to determine the genotype distribution, allele frequency, and prognostic impact of selected SNPs in MPNs.

Materials and Methods

The study included 130 MPN patients. The diagnosis of MPNs was performed based on World Health Organization and International Working Group criteria [11]. The Ege University Local Ethics Committee approved the study (13-5.1/8, 15.07.2013). Patient data were collected from the patient files.

SNP analysis was performed on DNA derived from peripheral blood samples that were collected into tubes containing EDTA between February 2008 and September 2009 and were stored at -80 °C until the DNA extraction. DNA extraction was performed using the MagNA Pure Compact Nucleic Acid Isolation Kit (Roche) according to the manufacturer's instructions. After DNA isolation, the purity and concentration of DNA was measured using a NanoDrop spectrophotometer (Thermo Scientific, USA) at 260 nm and 280 nm.

All SNP analysis was carried out with ready-to-use TaqMan assays from Life Technologies (USA): IDH1 [rs11554137-(C/T conversion)], IDH2 [rs121913503-(G/A conversion); rs267606870-(C/G conversion)], TET2 [rs763480-(A/T conversion)], and ASXL1 [rs2208131-(A/G conversion)]. Real-time polymerase chain reaction (PCR) reactions were performed according to the manufacturer's instructions using the ABI 7500 Fast Real-Time PCR instrument (Applied Biosystems, USA). The real-time PCR cycling conditions were: 95 °C for 10 min for enzyme activation, 40 cycles of 95 °C for 15 s (denaturation), and 60 °C for 1 min (annealing/extension). All assays were evaluated and genotyped using SDS software.

Statistical Analysis

Hardy-Weinberg equilibrium was used for each SNP. All p-values were two sided and p≤0.05 indicated statistical significance. Categorical and continuous variables were compared with chi-square statistics and the Mann-Whitney U test, respectively. Survival analysis was performed by the Kaplan-Meier method, taking the interval from the date of diagnosis to death or last contact. The log-rank test was used to compare the survival data.

Results

The demographic features of patients at the time of diagnosis are shown in Table 1. IDH2 (rs121913503) and IDH2 (rs267606870) SNPs were not detected in any of the patient groups; all of the cases were genotyped as wild-type homozygous (GG and CC, respectively, for the rs numbers). Two (1.5%) of all, 12 (9.2%) of all, and 3 (2.3%) of all patients were variant homozygous for TET2 (rs763480), ASXL1 (rs2208131), and IDH1 (rs11554137) SNPs, respectively (Table 2).

The TET2 mutant allele T frequency was 0.218 in the PV, 0.20 in the ET, and 0.272 in the PMF group. The ASXL1 mutant allele G frequency was 0.322 in the PV, 0.308 in the ET, and 0.25 in the PMF group. The IDH1 mutant allele T frequency was 0.073 in the PV, 0.108 in the ET, and 0.045 in the PMF group.

The median follow-up time was 8 years (range: 1-25). The estimated 10-year survival rate was 71% for ET, 87.3% for PV, and 71% for PMF patients (Figure 1). We did not find any significant differences between the diagnostic subgroups and the 10-year survival rates. At the time of the analysis, 5 and 10 patients had leukemic transformation and fibrotic transformation, respectively. There were no significant differences between the sexes, diagnoses, JAK2 mutation status (positive/negative), thrombosis status at diagnosis, survival rates, leukemic and fibrotic transformation, and genotyping results of ASXL1, TET2, and IDH1 (Table 3).

![Figure 1. Overall survival of different myeloproliferative neoplasm subgroups.](image-url)

ET: Essential thrombocythemia, PV: polycythemia vera, PMF: primary myelofibrosis.
In this study, we aimed to determine the genotype distribution, allele frequency, and prognostic impact of selected SNPs in MPNs. IDH mutation frequency was 2.5% in MPNs, 0.8% in ET, 1.9% in PV, 4.1% in PMF, and 1% in post-ET/PV-myelofibrosis patients [5]. Another study reported 3.7% IDH1 (G105G allele), 1.85% IDH2 R140Q, and 0.92% IDH2 (G145G allele) mutation in MPNs [12]. The frequency of the IDH1 (rs11554137) SNP in our cases was similar to that in the literature.

TET2 mutation frequency was 7.2%-13% in MPNs and was similar across different MPN subgroups. JAK2-positive patients (17%) had significantly higher TET2 mutation frequency [10,13]. In our series, TET2 (rs763480) frequency was higher in PMF patients.

ASXL1 mutation frequency was 10% in MPN patients. These mutations are rare in ET and PV (<7%) but frequent in PMF (19%-40%) [3,7]. In JAK2- and MPL-negative MPN patients, TET2 and ASXL1 mutation frequencies were 8% [14]. ASXL1 mutation frequency was 24.7% in PMF and 8.4% in ET patients [15]. ASXL1 mutation frequency was 12%-13% in PMF patients [16]. The frequency of the ASXL1 (rs2208131) SNP was 9.2% and this was similar between ET, PV, and PMF patients. We did not find any previous study that evaluated ASXL1 (rs2208131) and TET2 (rs763480) SNPs in MPNs.

Table 1. The demographic features of myeloproliferative neoplasm patients at the time of diagnosis.

| No of patients | MPN (n=130) | PV (n=48) | ET (n=60) | PMF (n=22) |
|----------------|-------------|-----------|-----------|------------|
| Age at diagnosis, years (range) | 63.5 (16-81) | 63.5 (16-74) | 63 (18-81) | 65 (31-74) |
| Sex, M/F | 72/58 | 30/18 | 29/31 | 13/9 |
| Thrombosis at diagnosis or before diagnosis, yes/no | 10/111 | 6/42 | 10/50 | 3/19 |
| Bleeding at diagnosis, yes | 5 | 2 | 2 | 1 |
| White blood cell count, x10^9/L (range) | 18.7 (3.1-73) | 18.7 (7.1-40.2) | 8.1 (4.8-43) | 33.9 (3-1.73) |
| Platelet count, x10^9/L (range) | 270.7 (88-2000) | 270.7 (95-1380) | 906.5 (325-2000) | 350 (88-1346) |
| Hemoglobin level, g/L (range) | 18 (6-23.4) | 18 (11.4-23.4) | 13.6 (8.8-16) | 13.8 (6-16.2) |
| LDH levels, normal/high | 70/52 | 26/18 | 40/17 | 4/17 |
| Splenomegaly, yes/no | 40/90 | 20/28 | 4/56 | 16/6 |
| Hepatomegaly, yes/no | 18/112 | 8/40v | 2/58 | 8/14 |
| JAK2V617F positive/negative | 82/43 | 46/2 | 30/30 | 11/11 |
| Secondary malignancies, yes | 2 | 0 | 2 | 0 |

Table 2. Genotype status of IDH1, IDH2, TET2, and ASXL1 single nucleotide polymorphisms in myeloproliferative neoplasm and myeloproliferative neoplasm subgroups.

| SNPs | MPN (n=130) | PV (n=48) | ET (n=60) | PMF (n=22) |
|------|-------------|-----------|-----------|------------|
| IDH2 (rs121913503) | Wild-type homozygous | 130 | 48 | 60 | 22 |
| IDH2 (rs267606870) | Wild-type homozyzous | 130 | 48 | 60 | 22 |
| IDH1 (rs11554137) | Wild-type homozygous | 111 (85.4%) | 41 (85.4%) | 50 (83.3%) | 20 (90.9%) |
| | Heterozygous | 16 (12.3%) | 7 (14.6%) | 7 (11.7%) | 2 (9.1%) |
| | Variant homozygous | 3 (2.3%) | 0 (0%) | 3 (5%) | 0 (0%) |
| TET2 (rs763480) | Wild-type homozygous | 75 (57.7%) | 27 (56.2%) | 37 (61.7%) | 11 (50%) |
| | Heterozygous | 53 (40.8%) | 21 (43.8%) | 22 (36.7%) | 10 (45.5%) |
| | Variant homozygous | 2 (1.5%) | 0 (0%) | 1 (1.7%) | 1 (5%) |
| ASXL1 (rs2208131) | Wild-type homozygous | 63 (48.5%) | 21 (43.8%) | 29 (48.3%) | 13 (59.1%) |
| | Heterozygous | 55 (42.3%) | 23 (47.9%) | 25 (41.7%) | 7 (31.8%) |
| | Variant homozygous | 12 (9.2%) | 4 (8.3%) | 6 (10%) | 2 (9.1%) |

**Discussion**

In this study, we aimed to determine the genotype distribution, allele frequency, and prognostic impact of selected SNPs in MPNs. IDH mutation frequency was 2.5% in MPNs, 0.8% in ET, 1.9% in PV, 4.1% in PMF, and 1% in post-ET/PV-myelofibrosis patients [5]. Another study reported 3.7% IDH1 (G105G allele), 1.85% IDH2 R140Q, and 0.92% IDH2 (G145G allele) mutation in MPNs [12]. The frequency of the IDH1 (rs11554137) SNP in our cases was similar to that in the literature.

TET2 mutation frequency was 7.2%-13% in MPNs and was similar across different MPN subgroups. JAK2-positive patients (17%) had significantly higher TET2 mutation frequency [10,13].
There was no relationship between \textit{TET2}, \textit{IDH1}, and \textit{ASXL1} SNPs and clinical and laboratory factors in our study. An impact of \textit{TET2} mutation on survival and leukemic transformation was not shown [10]. In normal karyotype acute myeloid leukemia, the \textit{IDH1} (rs11554137) SNP was an adverse prognostic factor [17]. In PMF, there was a significantly negative impact of \textit{IDH} mutations on survival [6]. \textit{ASXL1} mutations were identified in patients with PMF or post-ET/PV-myelofibrosis and associated with poor survival [8,9,15]. Whether the \textit{TET2}, \textit{IDH1}, and \textit{ASXL1} SNPs possibly confer any prognostic impact in MPN patients requires further evaluation.

The \textit{TET2} mutant allele T and \textit{ASXL1} mutant allele G had the highest frequencies at 0.272 in the PMF and 0.322 in the PV group, respectively. The \textit{ASXL1} and \textit{TET2} mutational statuses in the Turkish population are similar to those of the European population according to HapMap CEU data reporting 0.322 G mutant allele and 0.372 T mutant allele frequencies, respectively (hapmap.ncbi.nlm.nih.gov).

One of the limitations of this study is the small sample size. Since we did not evaluate \textit{MPL} and \textit{CALR} mutations, we could not assess whether there was a relationship between \textit{CALR} and \textit{MPL} mutations and these SNPs. Since we had no control group, we could not perform a comparison for these SNPs between patients and controls.

**Conclusion**

\textit{IDH1} frequency in MPNs was found to be similar to the rate reported in the literature. \textit{ASXL1} frequencies were similar between ET, PV, and PMF patients. We did not find an impact of the SNPs on survival, \textit{JAK2} status, or leukemic and fibrotic transformation. These findings suggest that \textit{IDH1} is a rare SNP in MPNs. The role of SNPs in MPNs might be further evaluated in larger multicenter studies.

**Authorship Contributions**

Surgical and Medical Practices: N.S., M.C.Ö., G.S.; Concept: N.S., B.T.K., B.K., G.S.; Design: N.S., B.T.K., B.K., G.S.; Data Collection or Processing: N.S., B.T.K., M.C.Ö., Ç.A., A.Ş.K., F.Ş., B.K., G.S.; Analysis or Interpretation: N.S., B.T.K., Ç.A., A.Ş.K.; Literature Search: N.S., B.T.K.; Writing: N.S., G.S.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

**References**

1. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006;63:2939-2953.
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-2466.
3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: \textit{JAK2}, \textit{MPX}, \textit{TET2}, \textit{ASXL1}, \textit{CBL}, \textit{IDH} and \textit{IKZF1}. Leukemia 2010;24:1128-1138.
4. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. \textit{IDH1} and \textit{IDH2} mutation analysis in chronic and blast phase myeloproliferative neoplasms. Leukemia 2010;24:1146-1151.
5. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland

---

**Table 3. Genotype status of \textit{IDH1}, \textit{TET2}, and \textit{ASXL1} single nucleotide polymorphisms and clinical and laboratory correlations.**

|                        | \textit{IDH1} (rs11554137) | p | \textit{TET2} (rs763480) | p | \textit{ASXL1} (rs2208131) | p |
|------------------------|---------------------------|---|-------------------------|---|---------------------------|---|
|                        | Wild-type (n=111)         |   | Heterozygous and variant (n=19) |   | Wild-type (n=75)         |   | Heterozygous and variant homzygous (n=65) |   | Wild-type (n=63)         |   | Heterozygous and variant homzygous (n=67) |   |
| Sex (M/F)              | 61/50                     |   | 11/8                    | NS | 37/38                     |   | 35/20                    | NS | 31/32                     |   | 41/26                    | NS |
| PV                     | 41                        | 7  | NS                      | 27 | 21                        | NS | 21                      | 31 | 29                      | 27 | NS                      |
| ET                     | 50                        | 10 | NS                      | 37 | 23                        | NS | 29                      | 27 | NS                      |
| PMF                    | 20                        | 2  | NS                      | 11 | 11                        | NS | 13                      | 9  | NS                      |
| Thrombosis at diagnosis| 17                        | 2  | NS                      | 11 | 8                         | NS | 9                       | 10 | NS                      |
| \textit{JAK2}, mutated vs. wild-type | 75/36                     |   | 12/7                    | NS | 50/25                     |   | 37/18                    | NS | 44/19                     |   | 43/24                    | NS |
| Overall survival (10-year) | 79.8%                     |   | 62.2%                    | NS | 75.3%                     |   | 80.4%                    | NS | 84.7%                     |   | 70.4%                    | NS |
| Leukemic transformation | 4                         | 1  | NS                      | 4  | 1                         | NS | 3                       | 2  | NS                      |
| Fibrotic transformation | 9                         | 1  | NS                      | 6  | 4                         | NS | 7                       | 3  | NS                      |

NS: Not significant, PV: polycythemia vera, ET: essential thrombocytemia, PMF: primary myelofibrosis.
DG, Levine RL, Pardanani A, Vannucchi AM. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24:1302-1309.

6. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, McClure RF, Pardanani A. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26:475-480.

7. Carbuccia N, Murati A, Troupin V, Brecqueville M, Adélaïde J, Rey J, Vainchenker W, Bernard OA, Chaffanet M, Vey N, Birnbaum D, Mozziconacci MJ. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-2186.

8. Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012;51:743-755.

9. Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012;26:1053-1064.

10. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullanly A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.

11. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.

12. Chotirat S, Thongnoppakhun W, Wanachaiwanawin W, Auewarakul CU. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. Blood Cells Mol Dis 2015;54:286-291.

13. Patriarca A, Colaizzo D, Tiscia G, Spadano R, Di Zacomo S, Spadano A, Villanova I, Margaglione M, Grandone E, Dragani A. TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. Biomed Res Int 2013;2013:929840.

14. Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann Hematol 2012;91:533-541.

15. Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yayuz AS, Sargin D. Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. J Blood Med 2015;6:157-175.

16. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, Beran M, Gilliland DG, Levine RL, Tefferi A. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-1202.

17. Wagner K, Damm F, Göhring G, Gürlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heit G, Ganser A, Krauter J. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356-2364.